Re: July 15, 2016

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: July 15, 2016

in response to

July 15, 2016

Stock2740

posted on Jul 06, 2016 08:58PM

I'm pretty sure Don mentioned July 31 as the official reorganization date in the webcast.

In other news, today marks 3 weeks from the first dosing of ZEN-3694. So based on the trial design, they should be increasing to the next dose level any day now, barring any setbacks.